Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin. Methods: In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR. Results: Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period. Conclusions: An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR.
Abstract
Background/Aims: The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin. Methods: In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR. Results: Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period. Conclusions: An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR.
참고문헌 (28)
- World Health Organization, "Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium", J Viral Hepat, 6, pp.35~47 (1999)
- Awad T, "Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials", Hepatology, 51, pp.1176~1184 (2010)
- Williams R, "Global challenges in liver disease", Hepatology, 44, pp.521~526 (2006)
- Thomas DL, "Natural history of hepatitis C", Clin Liver Dis, 9, pp.383~398 (2005)
- Strader DB, "The natural history of chronic hepatitis C infection", Eur J Gastroenterol Hepatol, 8, pp.324~328 (1996)
- Seeff LB, "National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002", Hepatology, 36(1), pp.1~2 (2002)
- Seeff LB, "Natural history of chronic hepatitis C", Hepatology, 36(1), pp.35~46 (2002)
- Liang TJ, "Pathogenesis, natural history, treatment, and prevention of hepatitis C", Ann Intern Med, 132, pp.296~305 (2000)
- Ghany MG, "American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Berenguer J, "Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus", Hepatology, 50, pp.407~413 (2009)
- George SL, "Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients", Hepatology, 49, pp.729~738 (2009)
- Hung CH, "Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis", J Viral Hepat, 13, pp.409~414 (2006)
- Desmond CP, "Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting", J Viral Hepat, 13, pp.311~315 (2006)
- Formann E, "Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy", Aliment Pharmacol Ther, 23, pp.507~511 (2006)
- Chavalitdhamrong D, "Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment", World J Gastroenterol, 12, pp.5532~5535 (2006)
- Giannini EG, "Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients", Aliment Pharmacol Ther, 31, pp.502~508 (2010)
- Swain MG, "A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin", Gastroenterology, 139, pp.1593~1601 (2010)
- 김철현, "만성 C형간염에서 인터페론", 페그인터페론과 리바비린 병합요법 후 지속바이러스반응 유지에 대한 고찰, 2009, pp.15(1), 70~79[DOI]
- 이장은, "만성 C형간염에서 지속적 바이러스 반응 이후의 재발:페그인터페론과 리바비린 병합 치료 후 지속적 바이러스 반응을 보인 환자에서 재발과 연관된 인자", 대한소화기학회지, 57(3), pp.173~179 (2011), 대한소화기학회
- McHutchison JG, "Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C", Gastroenterology, 123, pp.1061~1069 (2002)
- Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study", Hepatology, 45, pp.579~587 (2007)
- Cammà C, "Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach", J Hepatol, 34, pp.593~602 (2001)
- Cardoso AC, "Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis", J Hepatol, 52, pp.652~657 (2010)
- Morgan TR, "Outcome of sustained virological responders with histologically advanced chronic hepatitis C", Hepatology, 52, pp.833~844 (2010)
- Shiffman ML, "Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus", Oncology, 78(1), pp.11~16 (2010)